PROLIFERATIVE ADVANTAGE RATHER THAN CLASSICAL DRUG-RESISTANCE AS THE CAUSE OF TREATMENT FAILURE IN CHRONIC MYELOGENOUS LEUKEMIA

被引：6

作者：

PREISLER, HD

RAZA, A

BACCARANI, M

机构：

[1] Division of Hematology/Oncology, Rush Cancer Institute, Rush Presbyterian-St. Luke's Medical Center, Chicago

[2] Chair of Hematology, Udine University School of Medicine, Udine

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 11卷

关键词：

CHRONIC MYELOID LEUKEMIA; BLASTIC METAMORPHOSIS;

D O I：

10.3109/10428199309047903

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This presentation discusses the role that proliferative advantage plays in making both the chronic and blastic phases of CML resistant to therapy. A case is made for the addition of ''regrowth'' inhibitors between courses of chemotherapy as a means of increasing the efficacy of therapy by suppressing or reducing the proliferative advantage that the target cells enjoy over those cells which one would like to repopulate the hematopoietic system.

引用

页码：303 / 306

页数：4

共 20 条

[1]

Preisler H.D., Raza A., Larson R., Et al., Some reasons for the lack of progress in the treatment of acute myelogenous leukemia, Leuk. Res., 15, pp. 773-780, (1991)

[2]

Preisler H.D., Failure of remission induction in acute myelocytic leukemia, Med. Pediat., Oncol., 44, pp. 275-276, (1978)

[3]

Preisler H.D., Raza A., Higby I., Et al., Treatment of myeloid blastic crisis of chronic myelogenous leukemia, Cancer Treat. Rep., 68, pp. 1351-1355, (1984)

[4]

Kantarjian H., Walters R.S., Keating M.J., Et al., Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high dose cytosine arabinoside, Cancer, 62, pp. 672-676, (1988)

[5]

Goldman J.M., Catovsky D., Goolden A.W., Et al., Buffy coat autographs for patients with chronic granulocytic leukemia in transformation, Blut, 42, pp. 149-153, (1981)

[6]

Goldman J.M., Catovsky D., Hows J., Et al., Cryopreserved peripheral blood cells functioning as autografts in patients with chronic granulocytic leukemia in transformation, Br. Med. J., 191, 6174, pp. 1310-1313, (1979)

[7]

Sato H., Gottesman M.M., Goldstein L.J., Et al., Expression of the multidrug resistance gene in myeloid leukemias, Leuk. Res., 14, pp. 11-22, (1990)

[8]

Michieli M., Damiani D., Raspadori D., Et al., Over-expression of multidrug resistance associated P170 is usual during the course of Ph+ chronic myeloid leukemia, Proc. 2nd Int. Conf. CML, (1992)

[9]

Chandhary P.M., Roninson I., Expression and activity of p-glycoprotein, a multidrug efflux pump in human hematopoietic stem cells, Cell, 66, pp. 85-94, (1991)

[10]

Raza A., Khan S.P., Mehdi I., Et al., Cell Cycle Characterization in Myeloid Leukemia in Bone Marrow Transplantation, 4, pp. 26-29, (1989)

← 1 2 →